Turn Therapeutics Registers 25.4M Shares for Resale, ~83% of Outstanding, in S-3
TTRX has more than doubled off its 52-week low of $2.57.
Summary
Turn Therapeutics filed an S-3 to register 25,362,950 shares for resale — about 83% of its 30,572,704 shares outstanding — consolidating two prior S-1s and newly registering 873,000 shares. The company gets no proceeds from stockholder sales; its funding comes from the $85.0 million GEM equity line, of which roughly $75.0 million remains.
Key Events · Financing and Capital Events · TTRX
-
S-3 Registers 25.4M Shares for Resale
The shelf covers 25,362,950 shares: 17,868,760 carried over from the first S-1, 6,621,190 from the second, and 873,000 registered for the first time. The company sells no shares and receives no proceeds from stockholder sales.
-
Overhang Equals ~83% of Outstanding
The registered shares represent approximately 82.96% of the 30,572,704 shares outstanding as of November 6, 2026; the filing warns sales, or the perception of them, could significantly depress the trading price.
-
$85M GEM Equity Line Remains Main Funding
GEM committed up to $85.0 million at 90% of the 15-day average closing price (floor $1.00), with draw downs capped at 300% of average daily volume. About $4.07 million has been drawn and roughly $75.0 million remains; a second draw down for 272,642 shares was noticed October 29, 2026 with about $2.72 million advanced.
-
Cash Runway and Going Concern Context
The filing incorporates an auditor's report containing a going-concern explanatory paragraph; the Q3 10-Q reported $10.4 million of cash funding operations into Q3 2027, against a Phase 2b topline readout expected in the first quarter of 2027.
Analysis · TTRX · Life Sciences
This is a resale shelf, not a new share sale: the company receives nothing from selling stockholders' sales, but the registration makes a very large overhang tradable. The 25,362,950 shares covered equal roughly 83% of the 30,572,704 shares outstanding as of November 6, 2026, and the filing itself warns such sales, or the perception they may occur, could significantly depress the price. Most of the block is legacy: 17,868,760 shares carried over from the first S-1 and 6,621,190 from the second, with only 873,000 newly registered. The real cash mechanism is the GEM equity line — up to $85.0 million of stock at 90% of a 15-day average closing price, floor $1.00, with draw downs capped at 300% of average daily volume. About $75.0 million remains available after roughly $4.07 million drawn so far, and a second draw down for 272,642 shares was noticed October 29, 2026 with GEM advancing about $2.72 million. Against $10.4 million of cash and a going-concern explanatory paragraph in the auditor's report, this equity line is the company's main funding source for the Phase 2b readout expected in the first quarter of 2027 — and every draw down dilutes holders at a 10% discount to market.
How filings like this one have moved
In the 30 days to Nov 9, 2026, 47.1% of the 1533 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.29%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TTRX was trading at $9.48 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $289.5M. The 52-week trading range was $2.57 to $16.45. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.